BACKGROUND: Treatment resistance resulting from the presence of cancer stem cells (CSCs) remains a challenge in cancer treatment. Little is known about possible markers of CSCs in treatment-resistant non-small cell lung cancer (NSCLC). We explored the coxsackie-adenovirus receptor (CAR) as one such marker of CSCs in models of treatment-resistant NSCLC. MATERIALS AND METHODS: Resistant H460 and A549 cell lines were established by repeated exposure to paclitaxel or fractionated radiation. CSC markers were measured by Western blotting and flow cytometry. We also established stable CAR-overexpressing and stable shRNA-CAR-knockdown cell lines and assessed their survival, invasiveness, and tumorigenic capabilities with clonogenic, telomerase, Matrigel, and tumor formation assays. RESULTS: CAR expression was associated with CSC phenotype both in vitro and in vivo. CAR-overexpressing cells were more treatment-resistant, self-renewing, and tumorigenic than were parental cells, and shRNA-mediated knockdown of CAR expression was sufficient to inhibit these functions. CAR expression also correlated with the epithelial-mesenchymal transition. CONCLUSIONS: We showed for the first time that CAR is a marker of CSCs and may affect the activities of CSCs in treatment-resistant NSCLC. CAR may prove to be a target for CSC treatment and a predictor of treatment response in patients with NSCLC.
BACKGROUND: Treatment resistance resulting from the presence of cancer stem cells (CSCs) remains a challenge in cancer treatment. Little is known about possible markers of CSCs in treatment-resistant non-small cell lung cancer (NSCLC). We explored the coxsackie-adenovirus receptor (CAR) as one such marker of CSCs in models of treatment-resistant NSCLC. MATERIALS AND METHODS: Resistant H460 and A549 cell lines were established by repeated exposure to paclitaxel or fractionated radiation. CSC markers were measured by Western blotting and flow cytometry. We also established stable CAR-overexpressing and stable shRNA-CAR-knockdown cell lines and assessed their survival, invasiveness, and tumorigenic capabilities with clonogenic, telomerase, Matrigel, and tumor formation assays. RESULTS:CAR expression was associated with CSC phenotype both in vitro and in vivo. CAR-overexpressing cells were more treatment-resistant, self-renewing, and tumorigenic than were parental cells, and shRNA-mediated knockdown of CAR expression was sufficient to inhibit these functions. CAR expression also correlated with the epithelial-mesenchymal transition. CONCLUSIONS: We showed for the first time that CAR is a marker of CSCs and may affect the activities of CSCs in treatment-resistant NSCLC. CAR may prove to be a target for CSC treatment and a predictor of treatment response in patients with NSCLC.
Authors: Jin-Wen Chen; Bin Zhou; Qian-Chun Yu; Sangyoon J Shin; Kai Jiao; Michael D Schneider; H Scott Baldwin; Jeffrey M Bergelson Journal: Circ Res Date: 2006-03-16 Impact factor: 17.367
Authors: Naoki Hosen; Christopher Y Park; Naoya Tatsumi; Yusuke Oji; Haruo Sugiyama; Martin Gramatzki; Alan M Krensky; Irving L Weissman Journal: Proc Natl Acad Sci U S A Date: 2007-06-18 Impact factor: 11.205
Authors: Chenwei Li; David G Heidt; Piero Dalerba; Charles F Burant; Lanjing Zhang; Volkan Adsay; Max Wicha; Michael F Clarke; Diane M Simeone Journal: Cancer Res Date: 2007-02-01 Impact factor: 12.701
Authors: Carin K Ingemarsdotter; Laura A Tookman; Ashley Browne; Katrina Pirlo; Rosalind Cutts; Claude Chelela; Karisma F Khurrum; Elaine Y L Leung; Suzanne Dowson; Lee Webber; Iftekhar Khan; Darren Ennis; Nelofer Syed; Tim R Crook; James D Brenton; Michelle Lockley; Iain A McNeish Journal: Mol Oncol Date: 2014-12-29 Impact factor: 6.603
Authors: Xiaochun Zhang; Steven H Lin; Bingliang Fang; Michael Gillin; Radhe Mohan; Joe Y Chang Journal: J Thorac Oncol Date: 2013-12 Impact factor: 15.609
Authors: Nima Ghaderi; Joseph Jung; Sarah C Brüningk; Ajay Subramanian; Lauren Nassour; Jeffrey Peacock Journal: Int J Mol Sci Date: 2022-01-24 Impact factor: 5.923
Authors: Claudia Owczarek; Elena Ortiz-Zapater; Jana Kim; Efthymia Papaevangelou; George Santis; Maddy Parsons Journal: Front Oncol Date: 2022-02-14 Impact factor: 5.738